✦ LIBER ✦

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

✍ Scribed by A. H. V. Schapira; F. Stocchi; R. Borgohain; M. Onofrj; M. Bhatt; P. Lorenzana; V. Lucini; R. Giuliani; R. Anand; the Study 017 Investigators

Book ID: 117953323
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 548 KB
Volume: 20
Category: Article
ISSN: 1351-5101
DOI: 10.1111/j.1468-1331.2012.03840.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2.209 Long-term double-blind, placebo-co

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

✍ R. Anand; V. Lucini; R. Guiliani; S. Rossetti 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 68 KB

2.267 LONG-TERM EFFICACY OF SAFINAMIDE A

2.267 LONG-TERM EFFICACY OF SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE (PD) USING AN ‘ON’ AND ‘ON-OFF’ TREATMENT ANALYSIS

✍ R. Anand; R. Borgohain; M. Bhatt; F. Stocchi; D. Chirileanu; V. Lucini 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Long-Term Efficacy of Rasagiline in Earl

Long-Term Efficacy of Rasagiline in Early Parkinson's Disease

✍ Lew, Mark F.; Hauser, Robert A.; Hurtig, Howard I.; Ondo, William G.; Wojcieszek 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 267 KB

Efficacy, safety and tolerability of ras

Efficacy, safety and tolerability of rasagiline as an add-on therapy to dopamine agonists in early Parkinson's disease: The ANDANTE study

✍ Isaacson, S.; Silver, D.; Choudhry, A.; Hauser, R.A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Long-term safety and sustained efficacy

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease

✍ Hauser, R. A.; Schapira, A. H. V.; Barone, P.; Mizuno, Y.; Rascol, O.; Busse, M. 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 637 KB